ZYBAN SUMMARY
ZYBAN (bupropion hydrochloride) Sustained-Release Tablets are a non-nicotine aid to smoking cessation. ZYBAN is chemically unrelated to nicotine or other agents currently used in the treatment of nicotine addiction. Initially developed and marketed as an antidepressant (WELLBUTRIN® [bupropion hydrochloride] Tablets and WELLBUTRIN SR® [bupropion hydrochloride] Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.
ZYBAN is indicated as an aid to smoking cessation treatment.
|
NEWS HIGHLIGHTSMedia Articles Related to Zyban (Bupropion)
Smoking Cessation Program Offers Childhood Cancer Survivors Help To Quit The Habit
Source: Smoking / Quit Smoking News From Medical News Today [2009.11.17]
As smokers nationwide struggle to quit the habit, St. Jude Children's Research Hospital is offering assistance to those childhood cancer survivors who need help with smoking cessation. Despite the known health risks of tobacco use, about 18 percent of adults who survived childhood cancer are smokers-an average almost equal to that of the general population.
American Lung Association Urges Full Coverage Of Clinically Proven Smoking Cessation Treatments
Source: Respiratory / Asthma News From Medical News Today [2009.11.11]
As the debate over health care reform dominates the media and political arena, a new American Lung Association report finds that states aren't doing enough to help smokers quit - and policymakers must fix this in the health care reform process.
Medicaid Smoking Cessation Access on the Rise
Source: MedPage Today Psychiatry [2009.11.06]
Patients in 84% of the nation's Medicaid programs have access to tobacco-dependence treatment, but the availability and extent of coverage varied significantly, researchers found.
Published Studies Related to Zyban (Bupropion)
The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: A randomized controlled trial in unmotivated smokers. [2009.09.14]
Bupropion is an efficacious non-nicotine medication for smoking cessation; however, its cessation-mediating mechanism is unclear. This randomized, placebo-controlled trial examined the effect of bupropion SR (300mg/day for 6weeks) on plasma cotinine and on the subjective effects of smoking in 24 current daily smokers who were not trying to quit or reduce smoking...
A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. [2009.07]
INTRODUCTION: Studies examining the efficacy of tobacco dependence treatment among recovering alcoholic smokers have produced mixed findings... DISCUSSION: Treatment with bupropion SR among abstinent alcoholic smokers did not delay relapse or result in improved long-term smoking abstinence.
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. [2009.07]
The efficacy, safety and tolerability of bupropion XR and venlafaxine XR was assessed and compared with placebo in adult outpatients with major depressive disorder (MDD). Adults meeting DSM-IV criteria for MDD with a minimum Hamilton Depression Rating Scale (HAMD) 17-Item total score of > or =18 were randomized to eight weeks of double-blind treatment with either bupropion XR (150 mg/day), venlafaxine XR (75 mg/day) or placebo...
Sustained-release bupropion for hospital-based smoking cessation: a randomized trial. [2009.06]
INTRODUCTION: Bupropion is a first-line pharmacological aid for smoking cessation; however, no clinical trials have been conducted in a general population of hospitalized smokers.Because of the secular trend toward shorter hospital stays, recruitment was very difficult, raising questions regarding the feasibility of future hospital-based smoking cessation trials and interventions.
A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. [2009.01]
The present study investigated the efficacy of nefazodone and bupropion-sustained release for treating cannabis dependence. A double-blind, placebo-controlled, piggy back design was employed to assess if nefazodone and bupropion-sustained release increased the probability of abstinence from cannabis and reduced the severity of cannabis dependence and cannabis withdrawal symptoms during a 13-week outpatient treatment program...
Clinical Trials Related to Zyban (Bupropion)
Wellbutrin XL, Major Depressive Disorder and Breast Cancer [Completed]
- To evaluate the efficacy of bupropion extended release (Wellbutrin XLâ„¢) in the treatment
of Major Depressive Disorder in women with breast cancer.
- To evaluate the tolerability of bupropion extended-release (Wellbutrin XLâ„¢) in these
patients
The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity [Completed]
The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL
(bupropion hydrochloride) on reward processing.
Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation [Completed]
Background
Smokers often reject drugs as smoking cessation aids. Nonpharmacological interventions are
notoriously under-evaluated.
Methods
We conducted a randomized clinical trial in which we compared a medication, i. e.,
sustained-release bupropion (Zyban®; 413 subjects), at the time of the trial the most
efficacious pharmacological smoking cessation aid, with an ultrashort psychotherapeutic
intervention, Psychodynamic Model Training® (366 subjects), a manual-based psychodynamically
oriented 1 ½ day autosuggestion training. Outcome criterion was 12-month self-reported
continuous abstinence confirmed by urine cotinine levels below the level of detection (13
ng/ml) or, in an independent analysis, by exhaled carbon monoxide of 10 ppm or less at all
interviews conducted at 3, 6, and 12 months.
A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder [Completed]
The purpose of this pilot study is to determine the safety and potential efficacy of
sustained-release bupropion (Zyban®) for the treatment of nicotine dependence in patients
with bipolar affective illness. It is hypothesized that bupropion will produce a significant
enhancement of smoking abstinence compared to placebo and will be safe for use in these
patients.
Chantix & Bupropion for Smoking Cessation [Active, not recruiting]
The overarching goal of this line of research is to increase smoking abstinence rates using a
combination of existing pharmacotherapies. The aim of the current study is to assess the
safety and compliance as well as obtain preliminary estimates of efficacy and effect on
craving and nicotine withdrawal of combination therapy with bupropion SR and varenicline. We
will compare the efficacy estimates in this study with historical smoking abstinence rates
with varenicline. To accomplish our aims, we will enroll 38 cigarette smokers in an
open-label, phase II clinical trial.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 9 ratings/reviews, Zyban has an overall score of 6.67. The effectiveness score is 8.22 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Zyban review by 38 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Smoking Cessation |
| Dosage & duration: | | 150mg taken twice daily for the period of 4 Months |
| Other conditions: | | None |
| Other drugs taken: | | Birth Control | | |
Reported Results |
| Benefits: | | The drug did exactly what it was supposed to do. It completely eliminated all nicotine cravings leaving only the psychological aspect to worry about. So if I kept myself busy, the thought of smoking would never even enter my mind. |
| Side effects: | | For the first week or so, I was slightly hyperactive and had some trouble sleeping. That problem went away with some adjustment in the time I took the drug as well as with my bodies assimilation of the drug. I also had a mildly bad taste in my mouth. That too faded away. |
| Comments: | | I expressed to my doctor a desire to try this drug to quit smoking. She prescribed it to me and I began taking it shortly thereafter. Before my 2 week quit date had even arrived, I noticed a marked decrease in nicotine withdrawl episodes. I just didn't need to smoke. I found I was started to smoke only when I thought I "should" - after dinner, right before bed and other habitual times. Once I stopped smoking all together, it was a relief to only have to battle my habits and not the withdrawl effects of nicotine as well. |
|
| | Zyban review by 43 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | Moderate Side Effects | | |
Treatment Info |
| Condition / reason: | | Smoking |
| Dosage & duration: | | 1 tablet per day taken daily for the period of 10 weeks |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | I gave up smoking fo four months after taking Zyban for 10 weeks |
| Side effects: | | Zyban made me not care about smoking, it also made me not care about anything else, not exactly depressed - just nothing seemed worthwhle. |
| Comments: | | I took Zyban for 10 days before my quit day, then quit smoking and continued with the Zyban for a further 8 weeks. During that time I smoked on three or four occasions, mostly part of my husband's cigarette. I was really pleased with how I had done, and thought I had finally managed to kick the habit. But on holiday with a lot of smokers I gave in and smoked, thinking I would stop again when I got home - unfortunately that didn't happen. |
|
| | Zyban review by 45 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Ineffective |
| Side effects: | | Extremely Severe Side Effects | | |
Treatment Info |
| Condition / reason: | | smoking cessation |
| Dosage & duration: | | 150mg taken twice daily for the period of 10 days |
| Other conditions: | | none |
| Other drugs taken: | | none | | |
Reported Results |
| Benefits: | | none |
| Side effects: | | severe anxiety attacks, depression, suicidal thoughts. |
| Comments: | | I had to take 150mg daily for the 1st 5 days, then twice daily.
The tablets made me feel very anxious and depressed from day 6 onwards. I experienced a full blown anxiety attack on day 10, with racing thoughts that I could not control, suicidal thoughts, and a feeling that I was about to lose my mind. I had the presence of mind to realise that I was experiencing a reaction to the drug, but had to call a friend to spend the evening with me as I was experiencing a strong urge to kill myself. I discontinued the tablets, and the symptoms went away immediately |
|
|
|
Page last updated: 2009-11-17
|
